Study of the renal protective effect of tolvaptan as a replacement of loop diuretics for the treatment of ascites in cirrhotic patients with renal dysfunctio
Not Applicable
Recruiting
- Conditions
- liver cirrhosis
- Registration Number
- JPRN-UMIN000044693
- Lead Sponsor
- Tohoku Medical and Pharmaceutical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with active infections, including spontaneous bacterial peritonitis 2. Patients with carcinomatous peritonitis 3. Patients with chronic kidney disease or heart failure 4. Patients with hepatocellular carcinoma or esophagogastric varices within 6 months of treatment 5. Patients receiving vasopressin antagonist 6. Women who are pregnant, potentially pregnant, within 28 days after delivery, or breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in eGFR and serum creatinine levels after 12 weeks of administration of tolvaptan
- Secondary Outcome Measures
Name Time Method